BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marogianni C, Sokratous M, Dardiotis E, Hadjigeorgiou GM, Bogdanos D, Xiromerisiou G. Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease. Int J Mol Sci 2020;21:E8421. [PMID: 33182554 DOI: 10.3390/ijms21228421] [Cited by in Crossref: 7] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Li S, Lei Z, Sun T. The role of microRNAs in neurodegenerative diseases: a review. Cell Biol Toxicol 2022. [PMID: 36125599 DOI: 10.1007/s10565-022-09761-x] [Reference Citation Analysis]
2 Xing N, Dong Z, Wu Q, Kan P, Han Y, Cheng X, Zhang B. Identification and validation of key molecules associated with humoral immune modulation in Parkinson’s disease based on bioinformatics. Front Immunol 2022;13:948615. [DOI: 10.3389/fimmu.2022.948615] [Reference Citation Analysis]
3 Song LJ, Sui RX, Wang J, Miao Q, He Y, Yin JJ, An J, Ding ZB, Han QX, Wang Q, Yu JZ, Xiao BG, Ma CG. Targeting the differentiation of astrocytes by Bilobalide in the treatment of Parkinson's disease model. Int J Neurosci 2022;:1-18. [PMID: 36037147 DOI: 10.1080/00207454.2022.2100778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mysiris DS, Vavougios GD, Karamichali E, Papoutsopoulou S, Stavrou VT, Papayianni E, Boutlas S, Mavridis T, Foka P, Zarogiannis SG, Gourgoulianis K, Xiromerisiou G. Post-COVID-19 Parkinsonism and Parkinson’s Disease Pathogenesis: The Exosomal Cargo Hypothesis. IJMS 2022;23:9739. [DOI: 10.3390/ijms23179739] [Reference Citation Analysis]
5 Jing W, Xiaolan C, Yu C, Feng Q, Haifeng Y. Pharmacological effects and mechanisms of tannic acid. Biomed Pharmacother 2022;154:113561. [PMID: 36029537 DOI: 10.1016/j.biopha.2022.113561] [Reference Citation Analysis]
6 Levin LA, Patrick C, Choudry NB, Sharif NA, Goldberg JL. Neuroprotection in neurodegenerations of the brain and eye: Lessons from the past and directions for the future. Front Neurol 2022;13:964197. [DOI: 10.3389/fneur.2022.964197] [Reference Citation Analysis]
7 Nizamutdinov D, Ezeudu C, Wu E, Huang JH, Yi SS. Transcranial near-infrared light in treatment of neurodegenerative diseases. Front Pharmacol 2022;13:965788. [DOI: 10.3389/fphar.2022.965788] [Reference Citation Analysis]
8 Iori E, Mazzoli M, Ariatti A, Salviato T, Rispoli V, Valzania F, Galassi G. Myasthenia Gravis crossing Parkinson's Disease: a 20 year study from single Italian center. Int J Neurosci 2022;:1-10. [PMID: 35917141 DOI: 10.1080/00207454.2022.2107517] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kharrazian D. Functional Medicine Approaches to Neurodegeneration. Phys Med Rehabil Clin N Am 2022;33:733-43. [PMID: 35989061 DOI: 10.1016/j.pmr.2022.04.011] [Reference Citation Analysis]
10 Suhail M, Sohrab SS, Kamal M, Azhar EI. Role of hepatitis c virus in hepatocellular carcinoma and neurological disorders: an overview. Front Oncol 2022;12:913231. [DOI: 10.3389/fonc.2022.913231] [Reference Citation Analysis]
11 Guo M, Ji X, Liu J. Hypoxia and Alpha-Synuclein: Inextricable Link Underlying the Pathologic Progression of Parkinson's Disease. Front Aging Neurosci 2022;14:919343. [DOI: 10.3389/fnagi.2022.919343] [Reference Citation Analysis]
12 Shi Y, Wei B, Li L, Wang B, Sun M. Th17 cells and inflammation in neurological disorders: Possible mechanisms of action. Front Immunol 2022;13:932152. [DOI: 10.3389/fimmu.2022.932152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Watad A, McGonagle D, Anis S, Carmeli R, Cohen AD, Tsur AM, Ben-Shabat N, Lidar M, Amital H. TNF inhibitors have a protective role in the risk of dementia in patients with ankylosing spondylitis: Results from a nationwide study. Pharmacol Res 2022;:106325. [PMID: 35752359 DOI: 10.1016/j.phrs.2022.106325] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Cheng W, Song Y, Liu Y, Sun X, Ren W, Hashmi MF. Impact of Dexamethasone Preconditioning on Prevention of Development of Cognitive Impairment following Acute Inflammation. Contrast Media & Molecular Imaging 2022;2022:1-8. [DOI: 10.1155/2022/6064007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yang Z, Xue L, Li C, Li M, Xie A. Association between ABCA7 gene polymorphisms and Parkinson's disease susceptibility in a northern Chinese Han population. Neurosci Lett 2022;784:136734. [PMID: 35709878 DOI: 10.1016/j.neulet.2022.136734] [Reference Citation Analysis]
16 Cao F, Gui S, Gao X, Zhang W, Fu Z, Tao L, Jiang Z, Chen X, Qian H, Wang X. Research progress of natural product-based nanomaterials for the treatment of inflammation-related diseases. Materials & Design 2022;218:110686. [DOI: 10.1016/j.matdes.2022.110686] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Sudevan ST, Rangarajan TM, Al-Sehemi AG, Nair AS, Koyiparambath VP, Mathew B. Revealing the role of the benzyloxy pharmacophore in the design of a new class of monoamine oxidase-B inhibitors. Arch Pharm (Weinheim) 2022;:e2200084. [PMID: 35567313 DOI: 10.1002/ardp.202200084] [Reference Citation Analysis]
18 Zhang M, Li C, Ren J, Wang H, Yi F, Wu J, Tang Y. The Double-Faceted Role of Leucine-Rich Repeat Kinase 2 in the Immunopathogenesis of Parkinson’s Disease. Front Aging Neurosci 2022;14:909303. [DOI: 10.3389/fnagi.2022.909303] [Reference Citation Analysis]
19 Li D, Hong X, Chen T. Association Between Rheumatoid Arthritis and Risk of Parkinson's Disease: A Meta-Analysis and Systematic Review. Front Neurol 2022;13:885179. [DOI: 10.3389/fneur.2022.885179] [Reference Citation Analysis]
20 Zhou J, Ni W, Ling Y, Lv X, Niu D, Zeng Y, Qiu Y, Si Y, Wang Z, Hu J. Human neural stem cells secretome inhibits lipopolysaccharide-induced neuroinflammation through modulating microglia polarization by activating PPAR-γ. Stem Cells Dev 2022. [PMID: 35481777 DOI: 10.1089/scd.2022.0081] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zang X, Chen S, Zhu J, Ma J, Zhai Y. The Emerging Role of Central and Peripheral Immune Systems in Neurodegenerative Diseases. Front Aging Neurosci 2022;14:872134. [DOI: 10.3389/fnagi.2022.872134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
22 Parsafar S, Aliakbari F, Seyedfatemi SS, Najarzadeh Z, Hourfar H, Bardania H, Farhadpour M, Mohammadi M, Morshedi D. Insights into the inhibitory mechanism of skullcapflavone II against α-synuclein aggregation and its mediated cytotoxicity. Int J Biol Macromol 2022:S0141-8130(22)00562-1. [PMID: 35398391 DOI: 10.1016/j.ijbiomac.2022.03.092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Sammi SR, Jameson LE, Conrow KD, Leung MCK, Cannon JR. Caenorhabditis elegans Neurotoxicity Testing: Novel Applications in the Adverse Outcome Pathway Framework. Front Toxicol 2022;4:826488. [DOI: 10.3389/ftox.2022.826488] [Reference Citation Analysis]
24 Liu S, Wang Y, Jiang S, Wan X, Yan J, Liu C. Identifying the hub gene and immune infiltration of Parkinson’s disease using bioinformatical methods. Brain Research 2022. [DOI: 10.1016/j.brainres.2022.147879] [Reference Citation Analysis]
25 Domingues R, Sant’anna R, da Fonseca ACC, Robbs BK, Foguel D, Outeiro TF. Extracellular alpha-synuclein: Sensors, receptors, and responses. Neurobiology of Disease 2022. [DOI: 10.1016/j.nbd.2022.105696] [Reference Citation Analysis]
26 Zhao Y, Zhang X, Guo N, Tian D, Zhang C, Mu C, Han C, Zhu R, Zhang J, Liu X. Genetically Predicted Levels of Circulating Inflammatory Cytokines and the Risk and Age at Onset of Parkinson’s Disease: A Two-Sample Mendelian Randomization Study. Front Aging Neurosci 2022;14:811059. [DOI: 10.3389/fnagi.2022.811059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Yousefi-ahmadipour A, Sartipi M, Khodadadi H, Shariati-kohbanani M, Arababadi MK. Toll-like receptor 4 and the inflammation during aging. JGG 2022. [DOI: 10.36150/2499-6564-n471] [Reference Citation Analysis]
28 Yang Y, Zhang S, Guan J, Jiang Y, Zhang J, Luo L, Sun C. SIRT1 attenuates neuroinflammation by deacetylating HSPA4 in a mouse model of Parkinson's disease. Biochim Biophys Acta Mol Basis Dis 2022;:166365. [PMID: 35158021 DOI: 10.1016/j.bbadis.2022.166365] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Liu H, Salem Y, Aggarwal S. Effects of Tai Chi on biomarkers and their implication to neurorehabilitation – a systemic review. European Journal of Integrative Medicine 2022;50:101391. [DOI: 10.1016/j.eujim.2021.101391] [Reference Citation Analysis]
30 Siokas V, Aloizou AM, Liampas I, Bakirtzis C, Tsouris Z, Sgantzos M, Liakos P, Bogdanos DP, Hadjigeorgiou GM, Dardiotis E. Myelin-associated oligodendrocyte basic protein rs616147 polymorphism as a risk factor for Parkinson's disease. Acta Neurol Scand 2022;145:223-8. [PMID: 34694630 DOI: 10.1111/ane.13538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
31 Angelopoulou E, Paudel YN, Papageorgiou SG, Piperi C. Environmental Impact on the Epigenetic Mechanisms Underlying Parkinson’s Disease Pathogenesis: A Narrative Review. Brain Sciences 2022;12:175. [DOI: 10.3390/brainsci12020175] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
32 Toledo ARL, Monroy GR, Salazar FE, Lee JY, Jain S, Yadav H, Borlongan CV. Gut-Brain Axis as a Pathological and Therapeutic Target for Neurodegenerative Disorders. Int J Mol Sci 2022;23:1184. [PMID: 35163103 DOI: 10.3390/ijms23031184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
33 Alfonsetti M, Castelli V, d'Angelo M. Are We What We Eat? Impact of Diet on the Gut-Brain Axis in Parkinson's Disease. Nutrients 2022;14:380. [PMID: 35057561 DOI: 10.3390/nu14020380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Ramos-Martínez IE, Rodríguez MC, Cerbón M, Ramos-Martínez JC, Ramos-Martínez EG. Role of the Cholinergic Anti-Inflammatory Reflex in Central Nervous System Diseases. Int J Mol Sci 2021;22:13427. [PMID: 34948222 DOI: 10.3390/ijms222413427] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Yao C, Niu L, Fu Y, Zhu X, Yang J, Zhao P, Sun X, Ma Y, Li S, Li J. Cognition, motor symptoms, and glycolipid metabolism in Parkinson's disease with depressive symptoms. J Neural Transm (Vienna) 2021. [PMID: 34837534 DOI: 10.1007/s00702-021-02437-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Su R, Zhou T. Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson's Disease. Front Aging Neurosci 2021;13:769506. [PMID: 34803660 DOI: 10.3389/fnagi.2021.769506] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
37 Pereira TMC, Côco LZ, Ton AMM, Meyrelles SS, Campos-Toimil M, Campagnaro BP, Vasquez EC. The Emerging Scenario of the Gut-Brain Axis: The Therapeutic Actions of the New Actor Kefir against Neurodegenerative Diseases. Antioxidants (Basel) 2021;10:1845. [PMID: 34829716 DOI: 10.3390/antiox10111845] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
38 Bologna M, Truong D, Jankovic J. The etiopathogenetic and pathophysiological spectrum of parkinsonism. J Neurol Sci 2021;:120012. [PMID: 34642022 DOI: 10.1016/j.jns.2021.120012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
39 Yan Z, Yang W, Wei H, Dean MN, Standaert DG, Cutter GR, Benveniste EN, Qin H. Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease. Neurol Neuroimmunol Neuroinflamm 2021;8:e1036. [PMID: 34301818 DOI: 10.1212/NXI.0000000000001036] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
40 Yang Q, Zhuang J, Cai P, Li L, Wang R, Chen Z. JKAP relates to disease risk, severity, and Th1 and Th17 differentiation in Parkinson's disease. Ann Clin Transl Neurol 2021;8:1786-95. [PMID: 34289265 DOI: 10.1002/acn3.51420] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
41 Conte C. Possible Link between SARS-CoV-2 Infection and Parkinson's Disease: The Role of Toll-Like Receptor 4. Int J Mol Sci 2021;22:7135. [PMID: 34281186 DOI: 10.3390/ijms22137135] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
42 Krokidis MG, Exarchos TP, Vlamos P. Data-driven biomarker analysis using computational omics approaches to assess neurodegenerative disease progression. Math Biosci Eng 2021;18:1813-32. [PMID: 33757212 DOI: 10.3934/mbe.2021094] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Lee S, Suh YJ, Yang S, Hong DG, Ishigami A, Kim H, Hur JS, Chang SC, Lee J. Neuroprotective and Anti-Inflammatory Effects of Evernic Acid in an MPTP-Induced Parkinson's Disease Model. Int J Mol Sci 2021;22:2098. [PMID: 33672606 DOI: 10.3390/ijms22042098] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
44 Lv Q, Zhong Z, Hu B, Yan S, Yan Y, Zhang J, Shi T, Jiang L, Li W, Huang W. MicroRNA-3473b regulates the expression of TREM2/ULK1 and inhibits autophagy in inflammatory pathogenesis of Parkinson disease. J Neurochem 2021;157:599-610. [PMID: 33448372 DOI: 10.1111/jnc.15299] [Cited by in F6Publishing: 11] [Reference Citation Analysis]